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EDITORIAL COMMENT
Cyclooxygenase-2
Inhibitors and Atherosclerosis*
Orina Belton, PHD, Desmond Fitzgerald, MD
Dublin, Ireland
The report by Rott et al. (1) in this issue of the Journal adds
to the concerns surrounding the cardiovascular effects of
cyclooxygenase (COX)-2 inhibitors. However, their finding
of an increased burden of atherosclerosis in the apolipopro-
tein E (apoE) knockout mouse treated with a selective
COX-2 inhibitor must be seen in the context of other data
suggesting that COX-2 contributes to lesion formation or
has no effect whatsoever.
Prostaglandin (PG) generation and activity. Prosta-
glandins are generated from arachidonic acid by the enzyme
COX, which has two isoforms: COX-1 and COX-2. The
former is ubiquitously expressed and poorly inducible,
whereas the latter is largely absent from normal cells but is
induced by cytokines (2), growth factors (3), oxidized lipids
(4), and free radicals (5), factors known to play a role in
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atherosclerosis. That said, there is evidence that COX-1 is
inducible (6) and that COX-2 is expressed in normal
subjects. For example, COX-2 inhibitors reduce PGI2
formation in normal volunteers by up to 80% (7,8). Cy-
clooxygenases convert arachidonic acid to PG endoperox-
ides, which in turn are converted by a series of isomerases to
the corresponding PG. Cells tend to express a predominant
isomerase (prostacyclin synthase, thromboxane synthase,
PGE synthase, PGD synthase) closely coupled with COX,
which largely determines which product is generated. How-
ever, COXs can couple to different isomerases in the same
cell (9); cells can express more than one isomerase (10); and
there is evidence that endoperoxides generated in one cell
type may be metabolized by isomerases of adjacent cells,
so-called “transcellular metabolism” (11).
Prostaglandins mediate their effects through transmem-
brane G-protein–coupled receptors, several of which exist
for each PG (12). For example, there are at least four
different PGE-type receptors and two thromboxane A2
(TXA2) receptors (TP), the latter being alternatively spliced
variants derived from a single gene (13). As these are
cell-surface receptors, PGs presumably act in a paracrine or
autocrine fashion. They also activate peroxisome
proliferator-activated receptors (PPARs), nuclear mem-
brane proteins that dimerize with other cell proteins to form
transcription factors (14). In this way, PGs may act as
intracellular signaling molecules and regulate gene expres-
sion (15). There are at least four types of PPARs (alpha,
delta, gamma-1, and gamma-2) that exhibit differential
sensitivity to PGs (14). In short, in diseased tissue com-
posed of a variety of cells, a bewildering number of products
with diverse functions are generated. Consequently, the
effects of a COX inhibitor, acting high in this pathway, are
likely to be complex.
PGs and atherosclerosis. Cyclooxygenase expression
(16,17) and PG generation (17–19) are induced in patients
with atherosclerosis. Cyclooxygenase-2 is expressed in the
monocytes/macrophages and proliferating vascular smooth
muscle cells that typify atherosclerotic lesions, in addition to
endothelium (16,17). Patients with extensive disease have
enhanced formation of TXA2, a potent platelet activator
and vasoconstrictor, largely derived from COX-1 in plate-
lets (18). Formation of prostacyclin (PGI2), a potent platelet
inhibitor and vasodilator, is also increased largely through
COX-2 (17,19). Thus, in atherosclerosis, COX-2 inhibi-
tion preferentially suppresses PGI2 generation and spares
TXA2, as it also does in normal individuals (7,17). Theo-
retically, PGI2 may limit the extent of platelet adhesion and
activation at sites of vascular disease. For example, local
delivery of prostacyclin synthase using an adenoviral vector
reduces the platelet deposition seen following vascular injury
(20). In addition, disruption of the PGI2 receptor (IP)
enhances the response to carotid injury in the mouse. This
is largely dependent on TXA2, as coincident disruption of
the TP receptor prevents the amplification of vascular injury
(21). Given that PGI2 regulates the response to TXA2 and
COX-2 inhibition selectivity suppresses PGI2, it follows
that COX-2 inhibitors may enhance platelet activity. This
provides a plausible explanation for the increased risk of
myocardial infarction reported with the COX-2 inhibitor
called rofecoxib (22).
COX-2 inhibitors and atherosclerosis. There have been
reports that disruption of the IP receptor aggravates athero-
sclerosis in low-density lipoprotein receptor (LDLR)
knockout mice (23); furthermore, it has been suggested that
deletion of the IP receptor results in increased sensitivity to
thrombotic stimuli (24). However, as platelets contribute to
the development and progression of atherosclerosis, it fol-
lows that PGI2 formed locally may suppress lesion forma-
tion by limiting platelet deposition. Of course, COX-2
generates products other than PGI2, so the response to
COX-2 inhibitors may be quite different from those seen
when PGI2 is selectively inhibited. It should also be em-
phasized that targeted gene deletion of the IP receptor may
greatly exceed the effect achieved by COX-2 inhibitors,
where PGI2 generation is reduced but not ablated.
There are data demonstrating that COX-2 expressed in
monocytes/macrophages contributes to the development of
atherosclerosis in murine models (25) and to the expression
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of proteins, such as metalloproteinases, which contribute to
plaque instability (26). In that case, inhibition of COX-2
would be expected to limit the extent of atherosclerosis.
Indeed, Pratico et al. (23) reported a 30% reduction in
atherosclerosis by the COX-2 inhibitor nimesulide. Admin-
istration of the COX-2 inhibitor rofecoxib was also shown
to reduce atherosclerosis in a mouse model deficient in the
LDLR (25). In contrast, selective inhibition of COX-2 had
no effect on the restenosis that occurs following balloon
angioplasty of the rat carotid artery, whereas selective
inhibition of COX-1 reduced lesion formation, possibly
reflecting an antiplatelet effect (27). A role for COX-1–
mediated PGs is further supported by studies showing that
nonselective COX inhibitors, such as aspirin and indometh-
acin, retard the development of atherosclerosis in apoE/
mice (28) to a greater extent than a selective COX-2
inhibitor (25).
COX-2 and angiogenesis. Several PGs modulate angio-
genesis and endothelial cell apoptosis, both of which are
implicated in atherosclerosis (29). For example, PGE2 and
PGI2 induce endothelial cell growth and new blood vessel
formation (30), whereas TXA2 and PGJ2 have the opposite
effect (31). Both COX isoforms have been shown to play a
role in angiogenesis in several model systems. Selective
inhibition of COX-2 inhibits the growth of angiogenic
endothelial cells in vitro (32) and angiogenesis in animal
models of inflammation (33), whereas COX-1 activity in
endothelial cells modulates the angiogenesis that occurs
around transplanted tumors (34). In cardiovascular disease,
angiogenesis could have both beneficial and deleterious
effects. Angiogenesis may contribute to the revascularization
of ischemic tissues. On the other hand, angiogenesis in an
atherosclerotic lesion might result in plaque expansion and
vulnerability.
COX-2 as an anti-inflammatory gene. It is surprising,
therefore, that Rott et al. (1) found that inhibition of
COX-2 aggravated atherosclerosis in the apoE knockout
mouse. The study was more complex, as the authors set out
to examine the effect of COX-2 inhibition on infectivity of
cytomegalovirus and coincidentally showed increased dis-
ease burden in animals treated with the COX-2 inhibitor,
including those not infected with the virus. Although it
would be reasonable to conclude that this reflected selective
suppression of PGI2 and an unopposed effect of TXA2, the
authors suggest as an alternative hypothesis the suppression
of anti-inflammatory PGs, such as PGJ2, and its metabolite
15-deoxy-delta12,14-PGJ2 (15d-PGJ2) (35).
Although COX-2 is usually thought of as contributing to
inflammation, some authors have suggested that COX-2
may also play an anti-inflammatory role. The hypothesis
arises from observations with COX-2 inhibitors and in
animals in which the COX-2 gene has been disrupted.
Although inducing an anti-inflammatory effect acutely,
inhibition of COX-2 or disruption of the COX-2 gene can
aggravate inflammation chronically (36,37). For example, in
a rat model of carrageenan-induced pleurisy, Gilroy et al.
(37) found that COX-2 inhibitors, while suppressing in-
flammation initially, aggravated the inflammatory response
at 48 h after the injection of the antigen. These findings
have raised the possibility that COX-2 generates an anti-
inflammatory product, possibly 15d-PGJ2.
15d-PGJ2 is one of a series of products derived nonen-
zymatically from PGD2. Unlike other PGs, which are
pro-inflammatory, 15d-PGJ2 displays remarkable anti-
inflammatory effects (35). Several mechanisms have been
suggested, including induction of apoptosis in monocytes
(38), activation of PPAR-gamma, and modification of p50,
a subunit of the pro-inflammatory transcription factor,
nuclear factor kappa-B (39,40). Indeed, 15d-PGJ2 has been
found by immunoblot analysis in atherosclerotic plaque
(41). Given the structural similarities between different
PGs, immunologic identification is fraught with problems,
and more specific assays will be needed to demonstrate the
formation of PGJ2 and its metabolites. Highly specific
assays based on mass spectrometric identification of the
metabolites have shown that human cells are capable of
generating PGJ2 and its metabolites in an enzymatic fash-
ion, which is hardly surprising since these products derive
from PGD2 (42). What is unclear, as yet, is whether
sufficient amounts of the cyclopentenone PGs are generated
and remain in an active conformation to have any biologic
effect. Given their propensity to complex with peptides
(e.g., glutathione) and proteins, this is still in doubt.
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